WASHINGTON — House Democrats are signaling a robust oversight agenda should they secure control of either chamber in the upcoming midterm elections. Key health care issues, particularly those surrounding President Trump’s drug pricing initiatives, are poised to be at the forefront of this strategy.
Historically, newly empowered parties leverage oversight to shape narratives about their predecessors while simultaneously unifying their ranks by diverting attention from internal disputes. For Democrats, maintaining scrutiny on Trump—despite his inability to run again—serves as a strategic focal point to galvanize their base and highlight perceived missteps in health care policy.
Should they achieve a majority, Democrats will gain subpoena power, enabling them to compel administration officials and corporate leaders to testify. However, such efforts may encounter significant resistance from the current administration, setting the stage for potential confrontations in the legislative arena.
Use the database as your supply chain compass →
